Thirteen people have been infected with Vibrio vulnificus, the so-called "fleshing-eating" bacteria, according to a report.

Bristol Myers Squibb acknowledged that a phase III trial of luspatercept (Reblozyl) plus a Janus kinase inhibitor for ...